Header Logo

Connection

DAVID GRAHAM to Organometallic Compounds

Back to Details
This is a "connection" page, showing publications DAVID GRAHAM has written about Organometallic Compounds.
DAVID GRAHAM
Connection Strength
2.217
Organometallic Compounds
  1. Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori. Aliment Pharmacol Ther. 2005 Jan 15; 21(2):165-8.
    View in: PubMed
    Score: 0.221
  2. A pilot study evaluating high dose esomeprazole, bismuth subcitrate and amoxicillin for eradicating Helicobacter pylori infection in Iran. Helicobacter. 2024 Jan-Feb; 29(1):e13061.
    View in: PubMed
    Score: 0.206
  3. Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance. Aliment Pharmacol Ther. 2001 Apr; 15(4):513-8.
    View in: PubMed
    Score: 0.170
  4. Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study. Helicobacter. 2021 Jun; 26(3):e12801.
    View in: PubMed
    Score: 0.170
  5. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997 Oct; 11(5):935-8.
    View in: PubMed
    Score: 0.133
  6. Increasing role for modified bismuth-containing quadruple therapies for Helicobacter pylori eradication. Minerva Gastroenterol Dietol. 2017 06; 63(2):77-79.
    View in: PubMed
    Score: 0.127
  7. Azithromycin triple therapy for Helicobacter pylori infection: azithromycin, tetracycline, and bismuth. Am J Gastroenterol. 1995 Mar; 90(3):403-5.
    View in: PubMed
    Score: 0.111
  8. Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection. Am J Gastroenterol. 1994 Aug; 89(8):1203-5.
    View in: PubMed
    Score: 0.107
  9. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol. 1993 Nov; 28(11):939-42.
    View in: PubMed
    Score: 0.102
  10. Short report: a non-metronidazole triple therapy for eradication of Helicobacter pylori infection--tetracycline, amoxicillin, bismuth. Aliment Pharmacol Ther. 1993 Feb; 7(1):111-3.
    View in: PubMed
    Score: 0.097
  11. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992 Feb; 102(2):493-6.
    View in: PubMed
    Score: 0.090
  12. Simple noninvasive method to test efficacy of drugs in the eradication of Helicobacter pylori infection: the example of combined bismuth subsalicylate and nitrofurantoin. Am J Gastroenterol. 1991 Sep; 86(9):1158-62.
    View in: PubMed
    Score: 0.087
  13. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. Ann Intern Med. 1991 Aug 15; 115(4):266-9.
    View in: PubMed
    Score: 0.087
  14. Prevention of diarrhea caused by enterotoxigenic Escherichia coli: lessons learned with volunteers. Rev Infect Dis. 1990 Jan-Feb; 12 Suppl 1:S68-72.
    View in: PubMed
    Score: 0.078
  15. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States. Dig Liver Dis. 2004 Jun; 36(6):384-7.
    View in: PubMed
    Score: 0.053
  16. Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers. Gastroenterology. 1983 Nov; 85(5):1017-22.
    View in: PubMed
    Score: 0.051
  17. The QUADRATE study: a proposal for a change in the reporting of pharmaceutical supported trials. Gastroenterology. 2003 Aug; 125(2):639; author reply 640-1.
    View in: PubMed
    Score: 0.050
  18. Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen. Helicobacter. 2003 Aug; 8(4):307-9.
    View in: PubMed
    Score: 0.050
  19. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am J Gastroenterol. 2002 Apr; 97(4):857-60.
    View in: PubMed
    Score: 0.046
  20. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment Pharmacol Ther. 2000 Jun; 14(6):745-50.
    View in: PubMed
    Score: 0.040
  21. Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera? or Lactobacillus reuteri for treatment na?ve or for retreatment of Helicobacter pylori. Two randomized pilot studies. Helicobacter. 2019 Dec; 24(6):e12659.
    View in: PubMed
    Score: 0.038
  22. Helicobacter pylori infection and exaggerated gastrin release. Effects of inflammation and progastrin processing. Scand J Gastroenterol. 1993 Aug; 28(8):690-4.
    View in: PubMed
    Score: 0.025
  23. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med. 1992 May 01; 116(9):705-8.
    View in: PubMed
    Score: 0.023
  24. Ablation of exaggerated meal-stimulated gastrin release in duodenal ulcer patients after clearance of Helicobacter (Campylobacter) pylori infection. Am J Gastroenterol. 1990 Apr; 85(4):394-8.
    View in: PubMed
    Score: 0.020
  25. In vivo susceptibility of Campylobacter pylori. Am J Gastroenterol. 1989 Mar; 84(3):233-8.
    View in: PubMed
    Score: 0.018
  26. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med. 1999 Jul 20; 131(2):88-95.
    View in: PubMed
    Score: 0.009
  27. Is the sanctuary where Helicobacter pylori avoids antibacterial treatment intracellular? Am J Clin Pathol. 1997 Nov; 108(5):504-9.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.